

# **Efficacy of Metformin in Weight Management and Glycemic Control in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis**

## **Abstract**

**Introduction:** Type 2 diabetes mellitus (T2DM) is a chronic condition where obesity plays a key role. Metformin is commonly used to manage T2DM, with benefits in both glycemic control and weight management. This systematic review and meta-analysis update the evidence on metformin's impact on weight loss and glycemic control in T2DM patients.

**Objective:** To assess metformin's efficacy in reducing body weight and improving glycemic control in T2DM patients by synthesizing recent studies.

**Methods:** Following PRISMA guidelines, relevant studies were identified in PubMed, EMBASE, and clinicaltrials.gov. Fourteen randomized controlled trials and cohort studies, involving 11,686 T2DM patients, were analyzed using RevMan 5.4 software.

**Results:** Metformin led to a modest but significant reduction in body weight (Mean difference = 0.16; 95% CI: 0.69 to 1.02,  $p < 0.00001$ ) and significantly lowered glycosylated hemoglobin (A1C) and fasting plasma glucose (FPG) levels. Despite some study heterogeneity, the risk of bias was minimal.

**Conclusions:** Metformin is effective in modest weight reduction and significant glycemic control in T2DM patients, supporting its use as first-line therapy, especially for those who are overweight or obese.

**Keywords:** Type 2 diabetes, metformin, weight loss, glycemic control, systematic review.

## **Introduction**

The global burden of type 2 diabetes mellitus (T2DM) has reached epidemic proportions, with an estimated 463 million adults living with T2DM in the year 2019, and this number is expected to climb up to about 700 million by the year 2045 [1, 2]. The management of obesity is one of the more critical challenges around T2DM since the majority of patients with T2D are overweight or else obese. Obesity worsens insulin resistance, impairs glycemic control, and elevates the risk of cardiovascular complications [3]. Thus, knowledge about effective weight management strategies has become very important in the overall care of a patient with T2DM.

Since its introduction in the 1950s, metformin has been one of the mainstays for treating T2DM. Metformin is a biguanide-class drug. It works mainly by lowering hepatic glucose production and increasing insulin sensitivity. In addition to glucose lowering, metformin has generated considerable interest in its ability to reduce weight in T2DM [4, 5]. Various studies have proposed that, apart from the antihyperglycemic activity, metformin could result in modest weight loss, which would be an additional advantage in metabolic control in T2DM.

The intertwining of metformin and weight loss goes deep. This includes direct effects on appetite regulation and fat metabolism as well as indirect effects through improved insulin sensitivity and glycemic control [6, 7]. Indeed, metformin-induced weight loss will also be investigated to determine the extent and consistency of this phenomenon across various populations and different clinical frameworks.

Therefore, this updated systematic review and meta-analysis aims to critically appraise our available evidence on metformin as a weight-reduction strategy in people with T2DM. This review aims to collate the evidence from recent randomized controlled trials (RCTs) and observational studies to provide an up-to-date overview of metformin's efficacy in weight management for T2DM patients. The results of this review will apply to clinical practice, especially in forming treatment strategies for glycemic control and obesity among persons with T2DM.

## **Materials & Methods**

### ***Study Design***

The "Reporting Items for Systematic Review and Meta-Analysis (PRISMA)" guidelines were adhered to in a recent study [8]. Since the latest study was predicated on a systematic review and meta-analysis of previously published RCT trials, no extra ethical review was necessary.

### ***Selection Criteria***

PRISMA criteria were followed in selecting and screening research publications [9]. The screening of research articles was aided by the predetermined selection criteria.

### ***Inclusion Criteria***

Only those articles were included in the recent meta-analysis and systematic review that met the following criteria: 1). Discussing obese or non-obese populations having type 2 diabetes (DM2) 2). Discussing the efficacy or impact of metformin drugs for weight loss and glycemic control 3). Studies based on randomized controlled trials and cohort studies, 4). Studies with full text and published in English.

### ***Exclusion Criteria:***

Only the following studies were not included: 1. Talking about people who don't have diabetes or those with different kinds of diabetes 2. talking about the other anti-diabetic medication for glycemic control, cardiovascular risks, and weight loss 3. Systematic reviews, meta-analyses, scoping reviews, literature reviews, conferences, and case studies that have already been published 4. Studies with duplicate publications or non-full-text papers were published in languages other than English.

### ***Search Strategy***

The study aims of "Impact of metformin on weight loss in patients with type 2 diabetes" were addressed in research articles that were retrieved from several databases using the PRISMA criteria [2]. A recent systematic review and meta-analysis employed three electronic databases: clinicaltrials.gov, EMBASE, and PubMed. These MeSH terms were combined in the literature search. "Type 2 diabetes" OR "DM2" OR "obese diabetic patients" AND "metformin" OR "MET") AND "placebo" OR "sulfonylurea" OR "rosiglitazone" OR "miglitol" OR "Dapagliflozin") AND "weight loss" OR "BMI" OR "Glycosylated hemoglobin (A1C)" OR

"Fasting plasma glucose FPG" were the MeSH keywords used for data extraction. The study timeline was extended to January 2024.

### ***Study Question***

Among patients undergoing strabismus surgeries, what are the impacts of metformin on weight loss among type 2 diabetes patients? The recent study used the Population Intervention Control Outcome (PICO) framework to guide the search (Table 1).

**Table no. 1:** *PICO framework for research question of recent study*

| <b>PICO</b>            | <b>Description</b>  | <b>Search Terms</b>  |
|------------------------|---|--|
| Population             | Patients diagnosed with Type 2 Diabetes   | "type 2 diabetes" OR "DM2"<br>OR "obese diabetic patients"   |
| Intervention           | Metformin in monotherapy  | "metformin" OR "MET"   |
| Control/<br>comparison | Placebo and combination therapy   | "placebo" OR "sulfonylurea"<br>OR "rosiglitazone" OR<br>"miglitol"                                 |
| Outcome                | Loss in body weight (BMI), Decrease in Glycosylated hemoglobin (A1C), and Fasting plasma Glucose FPG (mmol/l) | "weight loss" OR "BMI" OR<br>"Glycosylated hemoglobin<br>(A1C)" OR "Fasting plasma<br>Glucose FPG" |

### ***Data Extraction***

Following the selection and screening of research articles, we extracted the demographic data pertaining to authors, study year, country, study population, sample size, study design, Intervention period, type of corticosteroid, and primary outcomes like body weight reduction and glycemic control from selected articles, as table no 02.

### ***Study Outcomes***

The primary outcomes of the recent study were related to the effectiveness of metformin in reducing body weight and glycemic control for type 2 diabetes mellitus patients. These outcomes were a reduction in body weight and glycemic control.

### *(a) Quality Assessment*

The critical appraisal skills program checklist (CASP) was used to perform a quality assessment, and it designed the overall judgment of the included studies. The Critical Appraisal Skills Programme introduced the CASP checklist for assessing the methodological quality of non-RCTs (prospective cohort study & Retrospective cohort study) [10]. Four included studies were entered into the quality assessment procedure by CASP to ensure the use of criteria uniformly.

### *(b) Risk of Bias Assessment*

The risk bias of the included RCTs was evaluated using the Cochrane risk of bias method [11]. Seven areas were used to assess the risk bias of included studies: allocation concealment, participant blinding, selection bias, blinding of outcome assessment, selective reporting, and additional bias. Each included study's score or level was divided into three categories: low risk, unclear risk, and high risk.

### *Statistical Analysis*


In a recent meta-analysis, the pooled analysis was conducted by using RevMan (Review Manager) software version 5.4. the Mantel-Haenszel (M-H) random effect model was applied [11] for evaluation of the mean difference of expected outcomes after metformin in comparison to placebo and other drugs in combination therapy for weight loss among type 2 diabetes patients was evaluated by pooled analysis. Furthermore, the I<sup>2</sup> statistics was used to measure the heterogeneity. A significant difference was considered if the p-value > 0.05. If the I<sup>2</sup> value was >50%, heterogeneity was considered significant.

## **RESULTS**

### **Included Studies**

The PRISMA standards in a recent meta-analysis were followed in selecting and screening research papers relevant to the study's objectives, "Impact of Metformin on Weight Loss in Patients with Type 2 Diabetes." In total, 1175 research articles were extracted from three electronic databases using the aforementioned search approach. Just 562 papers were examined using the PRISMA procedures, while 613 articles were disqualified before screening. Only 8 of those papers were evaluated for eligibility, and 14 research articles remained after exclusion

criteria were applied. As shown in Fig. no.1, only 14 papers were included in the most recent meta-analysis since they satisfied the inclusion criteria.



**Fig no. 1:** PRISMA Flowchart for screening and selection of included studies

**Risk of Bias & Quality Assessment**

The Cochrane risk of bias tool was used to assess the studies, and the findings are presented in Fig. 2 and 3. All our studies were considered to have minimal risk of bias, indicating a high level of reliability. The quality assessment of eleven studies was performed using the CASP checklist, which recognized 11 standards or questions for quality assessment. The scores of included studies were recorded in response to each standard; the study having a score of less than 5 was considered weak, a score of 5-7 was moderate, and more than 6 scores were a strong study. Among included studies, 2 studies [12, 21] were strong, 1 study [25] was moderate and 2 study [17] was weak, as shown in Table no. 2.

**Table no.2:** *The quality assessment of included studies by using CASP Checklist [3]*

| Standards of CASP checklist            | Myette et al., 2016 [9] | Ji et al., 2013 [18] | Abbasi et al., 2004 [10] | Ong et al., 2006 [14] |
|--|-------------------------|----------------------|--------------------------|-----------------------|
| Focused issue                          | Y                       | Y                    | Y                        | Y                     |
| Appropriate methodology related to aim | Y                       | Y                    | Y                        | N                     |
| Data resources linked authenticity     | N                       | Y                    | Y                        | N                     |
| selection of control group             | Y                       | N                    | Y                        | N                     |
| Negligence to Bias                     | Y                       | N                    | N                        | Y                     |
| Considering confounding factors        | Y                       | Y                    | Y                        | N                     |
| Clarity of results                     | Y                       | Y                    | N                        | N                     |
| Result Accuracy                        | Y                       | Y                    | Y                        | Y                     |
| Model validation                       | N                       | Y                    | Y                        | Y                     |
| Applicability Of study                 | Y                       | N                    | Y                        | N                     |
| Fitness of results                     | Y                       | Y                    | Y                        | N                     |
| Total score                            | 9                       | 8                    | 9                        | 4                     |




Fig no.2: Graph of Risk bias of included studies

UNDER PEER REVIEW

|                       | Adequate sequence generation? | Allocation concealment? | Blinding? | Incomplete outcome data addressed? | Free of selective reporting? | Free of other bias? |
|-----------------------|-------------------------------|-------------------------|-----------|------------------------------------|------------------------------|---------------------|
| Bolinder et al., 2012 | +                             | -                       | +         | -                                  | +                            |                     |
| Chiasson et al., 2001 | -                             | +                       | +         | +                                  |                              | +                   |
| Chukir et al., 2021   | +                             |                         | -         |                                    | +                            |                     |
| Erikson et al., 2006  |                               | +                       | +         |                                    |                              |                     |
| Fonseca et al., 2000  |                               | +                       |           |                                    | -                            | -                   |
| Gram et al., 2011     | -                             | +                       | +         | -                                  | -                            |                     |
| Hermann et al., 2001  | +                             | +                       | +         | -                                  | -                            | -                   |
| Jones et al., 2002    | -                             | -                       | +         |                                    | +                            | +                   |
| Kawai et al., 2008    | -                             | +                       | +         | +                                  | -                            |                     |
| Kooy et al., 2009     | +                             |                         | +         | -                                  | -                            |                     |
| Rachmani et al., 2002 | +                             |                         | +         | -                                  | -                            |                     |

Fig no. 3: Graph of risk bias summary of included studies

### 3.3 Characteristics of Included Studies

In a recent meta-analysis, studies involving metformin drugs for weight loss among type 2 diabetes mellitus were included to evaluate its effectiveness. To produce heterogeneity, 10 RCT's and 4 non RCT's involving 11686 type 2 diabetes mellitus patients were taken from 10 different countries such as 4 from USA[13, 14, 17, 18], 3 from Sweden[19,20,24], 1 from Denmark [12], 1 from Netherland [815], 1 from Canada [16], 1 from Australia [21], 1 from Israel [22], 1 from China [25] and 1 from Japan [26].

Table no. 3: Characteristics of included studies in recent systematic review and meta-analysis

| Author, Year             | Country         | Study Population                               | Sample size                         | Study design                | Type of Intervention (dose up to 1000mg)          | Study follow up | Glycosated hemoglobin (A1C)                | Fasting plasma Glucose FPG (mmol/l)      | Decrease in BMI (kg/m <sup>2</sup> )  |
|--------------------------|-----------------|--|-------------------------------------|-----------------------------|---|-----------------|--|--|---------------------------------------|
| Gram et al., 2011 [12]   | Denmark         | 371 Type 2 diabetes patients (30–70 years old) | 37 in metformin & 40 in placebo     | Randomized controlled trial | Metformin   | 2 years         | T: $-0.60 \pm 0.10$<br>C: $-0.41 \pm 0.10$ | T: $1.9 \pm 5.7$<br>C: $6.7 \pm 9.9$     | T: $2.8 \pm 0.6$<br>C: $-1.6 \pm 0.6$ |
| Chukir et al., 2021 [13] | USA             | 222 type 2 diabetes patients                   | 103 in treatment<br>119 in placebo  | Retrospective cohort study  | Metformin monotherapy                             | 12 months       |  |  | T: 6.5 [6.0%]<br>C: 7.4 [6.2%]        |
| Jones et al., 2002 [14]  | California, USA | 481 type 2 diabetes (8–16 years)               | 42 in treatment<br>40 in placebo    | Randomized controlled trial | Metformin monotherapy                             | 16 weeks        | T: 7.5<br>C: 8.6                           | T: $-2.4$<br>C: $+1.2$                   | T: $-0.5$<br>C: $-0.4$                |
| Kooy et al., 2009 [15]   | Netherlands     | 390 patients (30-80 years)                     | 196 in treatment<br>194 in placebo  | Randomized controlled trial | Metformin   | 4 years         | T: $-0.55$<br>C: $-0.25$                   | T: 2.1<br>C: 2.6                         | T: $-1.37$<br>C: $-0.81$              |
| Myette et al., 2016 [16] | Canada          | 10 DM2 patients (40-70 years old)              |                                     | Pilot study                 | Metformin   | 6 years         | T: $6.6 \pm 0.6\%$                         | T: -1.1<br>C: 0.3                        | T: -2.9.<br>C: 1.2                    |
| Abbasi et al., 2004 [17] | CA, USA         | 31 DM2 patients                                | 16 in metformin & 15 in combination | Prospective study           | Metformin plus sulfonylurea (combination therapy) | 12 weeks        | T: $2.91 \pm 0.47$<br>C: $3.52 \pm 0.85$   | T: $0.43 \pm 0.09$<br>C: $0.34 \pm 0.07$ |                                       |

|                            |                |                                    |   |  |                               |           |                                    |                                   |                                    |
|----------------------------|----------------|------------------------------------|---|--|-------------------------------|-----------|------------------------------------|-----------------------------------|------------------------------------|
|                            |                |                                    | therapy                                       |  |                               |           |                                    |                                   |                                    |
| Fonseca et al., 2000 [18]  | Louisiana, USA | 348 DM2 (40-80 years)              | 116 in metformin & 119 in combination therapy | Randomized, double-blind, placebo-controlled trial | Metformin plus rosiglitazone  | 26 weeks  | T: 1.0<br>C: 1.2                   | T: 2.2 mmol/L<br>C: 2.9 mmol/L    |                                    |
| Bolinder et al., 2012 [19] | Sweden         | 314 DM2 patients                   | 91 in metformin & 89 in combination therapy   | Randomized controlled trial                        | Metformin plus Dapagliflozin  | 24 week   | T: -0.10<br>C: -0.39               | T: 2.4 (0.13)<br>C: -14.7 (-0.82) | T: -2.22<br>C: -0.74               |
| Erikson et al., 2006 [20]  | Sweden         | 21 DM2 patients                    | 16 in metformin<br>5 in placebo               | Randomized controlled trial                        | Metformin                     | 4 weeks   | T: 0.7<br>C: -0.12                 | T: 2.04<br>C: 1.06                |                                    |
| Ong et al., 2006 [21]      | Australia      | 8,304 individuals                  | 394 in metformin & 250 in combination therapy | Prospective study                                  | Metformin versus Sulfonylurea | 5 years   | T: -1.3<br>C: -0.97                |                                   | T: -16.07<br>C: -2.3               |
| Rachmani et al., 2002 [22] | Israel         | 393 patients (40-75 years)         | 195 in metformin & 198 in placebo             | Randomized controlled trial                        | Metformin                     | 2 weeks   | T: 5.8<br>C: 2.3                   |                                   | T: 4.2<br>C: 1.3                   |
| Chiasson et al., 2001 [23] | France         | 324 DM 2 patients (40 to 60 years) | 83 in metformin, 76 in combination therapy    | Randomized controlled trial                        | Metformin plus miglitol       | 8 week    | T: -0.85 ± 0.12<br>C: -1.39 ± 0.11 | T: -17.4 ± 4.7<br>C: -12.4 ± 3.8  | T: -0.79 ± 0.33<br>C: -1.87 ± 0.33 |
| Hermann et al., 2001 [24]  | Sweden         | 37 DM2 patients                    | 16 in metformin & 16 in                       | Randomized controlled trial                        | Metformin                     | 12 months | T: -1.1 ± 0.7%<br>C: 0.3 ± 0.8%    | T: -1.4 ± 2.1<br>C: 0.6 ± 2.2     |                                    |

|                         |       |                                      |                                    |                              |                             |          |                                      |                                    |                                    |
|-------------------------|-------|--------------------------------------|------------------------------------|------------------------------|-----------------------------|----------|--------------------------------------|------------------------------------|------------------------------------|
|                         |       |                                      | placebo                            |                              |                             |          |                                      |                                    |                                    |
| Ji et al., 2013 [25]    | China | 371 DM2 patients with obesity        | 233 in metformin<br>112 in placebo | Prospective open label trial | Metformin                   | 16 weeks | T: -1.78 (-1.67)<br>C: -1.84 (-1.73) | T: -2.14 (2.03)<br>C: -1.98 (1.79) | T: -1.04 (1.11)<br>C: -0.54 (0.84) |
| Kawai et al., 2008 [26] | Japan | 69 Japanese type 2 diabetic patients | 35 in metformin & 28 in placebo    | Randomized controlled trial  | Metformin plus Pioglitazone | 24 weeks | T: 0.6% ± 0.1<br>C;                  | T: -18.5<br>C: - 3.5               | T: 0.2± 3.4<br>C: 0.1±1.2          |

UNDER PEER REVIEW

## Primary Outcome

### Glycosylated hemoglobin (A1C)

Among 14 included studies, the outcome of glycosylated hemoglobin (A1C) was discussed among 7 research articles on metformin versus placebo [12, 14-19] and 6 research articles on metformin versus other antibiotic drugs [20-25]. There was a significant difference in glycosylated hemoglobin (A1C) levels among metformin and placebo groups (Mean difference = 0.69; -0.93 to 2.23 CI: 95%,  $p < 0.00001$ ). However, there was a slight difference in glycosylated hemoglobin (A1C) (Mean difference = 0.36; -0.08 to 0.34, CI; 95,  $p, 0.00001$ ) among groups receiving metformin and another antidiabetic drug such as miglitol, rosiglitazone, and heterogeneity was found ( $df = 13$ ;  $I^2 = 99\%$ ), as shown in fig no 4 and 5. The mean difference values of the pooled analysis showed that metformin drugs have not reduced A1C levels among type 2 diabetes patients.




Fig no. 4: Forest plot of mean difference of A1C levels among metformin and placebo or other antibiotic drug[12, 26]




Fig no. 5: Funnel plot of mean difference of A1C levels among metformin and placebo or other antibiotic drug

### Fasting plasma glucose FPG

Among 14 included studies, the outcome of Fasting plasma Glucose FPG was discussed among 7 research articles of metformin versus placebo [12, 14-19] and 5 research articles of metformin versus other antibiotic drugs [20, 22-26]. There was a significant difference in fasting plasma glucose levels among metformin and placebo groups (Mean difference = -1.38; -2.78 to 2.23 CI: 95%,  $p < 0.00001$ ). However, there was a significant difference in FPG (Mean difference -6.49; -9.943 to 3.34, CI; 95,  $p, 0.00001$ ) among groups receiving metformin and other antidiabetic drug such as miglitol, rosiglitazone, and heterogeneity was found ( $df = 1$ ;  $I^2 = 33.1\%$ ), as shown in fig no 6 and 7.




Fig no. 6: Forest plot of mean difference of FPG levels among metformin and placebo or other antidiabetic drug [12-26]




Fig no. 7: Funnel plot of mean difference of FPG levels among metformin and placebo or other antidiabetic drug

### **Weight loss**

Among 14 included studies, the outcome of body weight or BMI was discussed among 7 research articles of metformin versus placebo [12, 14-19] and 4 research articles of metformin versus other antidiabetic drugs [20, 22-23, 25]. There was a slight difference in body weight loss among metformin and placebo groups (Mean difference = 0.16; 0.69 to 1.02 CI: 95%,  $p < 0.00001$ ). However, there was a significant difference in FPG (Mean difference -3.67; -11.58 to 4.34, CI: 95,  $p < 0.00001$ ) among groups receiving metformin and other antidiabetic drug such as miglitol, rosiglitazone, and heterogeneity was found ( $df = 9$ ;  $I^2 = 100\%$ ), as shown in fig no 8 and 9.





Fig no. 8: Forest plot of mean difference of Metformin versus placebo and Metformin versus metformin, other anti diabetic drugs [12-16, 19-26]



**Fig. 9 Placebo effect of metformin with other anti-diabetic drugs**

## Discussion

The present updated meta-analysis provides an overview of the weight loss effects associated with metformin in patients diagnosed with T2DM. Findings show that metformin induces minor weight and hemoglobin A1c levels reductions but is more effective than other antidiabetic agents.

This analysis indicates that metformin reduces body weight slightly among T2DM patients. This was consistent with prior literature, which has shown metformin to be weight-neutral or even cause a small degree of weight loss when taken by overweight/obese diabetic patients. The average difference of a few kilograms in weight loss between metformin and placebo groups is not great but clinically meaningful. An essential point is that obesity can exacerbate insulin resistance and further complicate diabetes management. This is crucial as weight loss reduces

cardiovascular risks and improves overall metabolic health compared to other antidiabetic medications that may have the potential to increase body weight.[27,28]

The pooled data support the effectiveness of metformin in decreasing glycosylated hemoglobin (A1C) levels. The metformin groups had significantly lower A1C, an important marker of long-term glycemic control compared with placebo. This further confirms that metformin improves insulin sensitivity and decreases intrahepatic glucose production. The pronounced lowering of fasting plasma glucose (FPG) seen here also underscores the concept that metformin is optimal for treating patients with their initial hyperglycemia and defines its role as first-line therapy in T2DM [29].

Metformin is much better than other antidiabetic agents like sulfonylureas, rosiglitazone, and miglitol in terms of weight management. Although some of these drugs have been linked with weight gain, metformin either has a neutral effect on body weight or causes modest weight loss. Horizontal gene transfer is especially good; one of the big problems with many antidiabetic drugs is that they cause weight gain, which can exacerbate insulin resistance and other metabolic ills. So, the glycemic control and weight reduction effects of metformin both confer individual advantages in T2DM cohorts [30, 31]

The high degrees of heterogeneity identified in the selected studies emphasize variance between study designs, populations, and intervention durations. In light of that, the risk of bias was generally low, and most studies were of high quality. This increases the robustness of our conclusions but also points towards the impact of patient-specific characteristics (age, baseline BMI, DT2 duration) on outcomes. To counter any risk of bias, reviewed articles were formally assessed using the CASP checklist and Cochrane risk of bias tool for randomized controlled trials to ensure that they met rigorous standards with regard to methodological quality [32].

### **Clinical Implications**

The implications of these findings are monumental for clinical practice. As metformin is a drug inducing weight loss with relatively modest effects compared to its primary glucose-lowering effect, it confirms the importance of using this agent in overweight or obese patients. Metformin has been shown to have this dual benefit, so there is evidence amongst others for still using

metformin as a first-line therapy. Clinicians should be mindful of prescribing metformin in light of these findings not only for the glucose-lowering properties but also due to its possible assistance with weight management, a clinically relevant agent that is critical within T2DM development.

### **Limitations and Future Research**

Although the meta-analysis provides essential information, there are limitations that future studies might possibly be able to address. The marked heterogeneity in metabolic benefits undoubtedly emerged, and consequently, more granular segregation by readily available patient characteristics such as age, gender, or baseline metabolism might possibly be subjected to further stratified analyses. Further, long-term studies are warranted to appraise the durability of metformin-induced weight loss and glycemic control processes. Consequently, future research should seek to further elucidate the pathways by which metformin accomplishes weight loss to enable an optimal individualization of diabetes treatment and different therapeutic regimens.

### **Conclusion**

In conclusion, this updated systematic review and meta-analysis confirm that metformin results in a small weight reduction among T2DM patients concurrent with its well-accepted advantage relating to glycemic control. The beneficial effect on body weight, in addition to the safety and cost-effectiveness of metformin, reinforces its use as a first-line therapy alongside regular exercise for the management of T2DM. Their results endorse metformin as a first-line treatment, especially for overweight or obese type 2 diabetic individuals, and emphasize the importance of continued research to enhance this therapeutic utility.

### **Disclaimer (Artificial intelligence)**

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

- 1.
- 2.
- 3.

UNDER PEER REVIEW

## References

1. Kawai T, Funae O, Shimada A, Tabata M, Hirata T, Atsumi Y, Itoh H: Effects of Pretreatment with Low-dose Metformin on Metabolic Parameters and Weight Gain by Pioglitazone in Japanese Patients with Type 2 Diabetes. *Internal Medicine*. 2008, 47:1181–8. <https://doi.org/10.2169/internalmedicine.47.0969>
2. Khan MA, Hashim MJ, King J, Govender RD, Mustafa H, Al Kaabi J: Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends. *Journal of Epidemiology and Global Health*. 2020, 10:107–11.
3. Susan, Talbot ML, Jorgensen JO: EFFICACY OF SURGERY IN THE MANAGEMENT OF OBESITY-RELATED TYPE 2 DIABETES MELLITUS. *ANZ journal of surgery/ANZ journal of surgery*. 2007, 77:958–62. <https://doi.org/10.1111/j.1445-2197.2007.04290.x>
4. Lalau JD, Azzoug ML, Kajbaf F, Briet C, Desailoud R: Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation. *Diabetes & Metabolism*. 2014, 40:220–3. <https://doi.org/10.1016/j.diabet.2013.12.003>
5. Malin SK, Kashyap SR: Effects of metformin on weight loss. *Current Opinion in Endocrinology & Diabetes and Obesity*. 2014, 21:323–9. <https://doi.org/10.1097/med.0000000000000095>
6. Khan MA, Hashim MJ, King J, Govender RD, Mustafa H, Al Kaabi J: Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends. *Journal of Epidemiology and Global Health*. 2020, 10:107–11.
7. Alfaraidi H, Samaan MC. Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review. *Front Endocrinol*. 2023;13:1072879.
8. Tetzlaff J, Page M, Moher D: THE PRISMA 2020 STATEMENT: DEVELOPMENT OF AND KEY CHANGES IN AN UPDATED GUIDELINE FOR REPORTING SYSTEMATIC REVIEWS AND META-ANALYSES. *Value in Health*. 2020, 23:S312–3. <https://doi.org/10.1016/j.jval.2020.04.1154>

9. Sarkis-Onofre R, Catalá-López F, Aromataris E, Lockwood C: How to Properly Use the PRISMA Statement. *Systematic Reviews*. 2021, 10: <https://doi.org/10.1186/s13643-021-01671-z>
10. Long HA, French DP, Brooks JM: Optimising the Value of the Critical Appraisal Skills Programme (CASP) Tool for Quality Appraisal in Qualitative Evidence Synthesis. *Research Methods in Medicine & Health Sciences*. 2020, 1:31–42.
11. Higgins JPT, Altman DG, Gotzsche PC, et al.: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011, 343: <https://doi.org/10.1136/bmj.d5928>
12. Gram J, Henriksen JE, Grodum E, et al.: Pharmacological Treatment of the Pathogenetic Defects in Type 2 Diabetes. *Diabetes Care*. 2010, 34:27–33. <https://doi.org/10.2337/dc10-0531>
13. Chukir T, Mandel L, Tchang BG, et al.: Metformin-induced weight loss in patients with or without type 2 diabetes/prediabetes: A retrospective cohort study. *Obesity Research & Clinical Practice*. 2021, 15:64–8. <https://doi.org/10.1016/j.orcp.2020.12.005>
14. Jones KL, Arslanian S, Peterokova VA, Park J-S, Tomlinson MJ: Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. *Diabetes care*. 2002, 25:89–94. <https://doi.org/10.2337/diacare.25.1.89>
15. Kooy A, de Jager J, Lehert P, Bets D, Wulffélé MG, Donker AJM, Stehouwer CDA: Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus. *Archives of Internal Medicine*. 2009, 169:616. <https://doi.org/10.1001/archinternmed.2009.20>
16. Myette-Côté É, Terada T, Boulé NG: The Effect of Exercise with or Without Metformin on Glucose Profiles in Type 2 Diabetes: A Pilot Study. *Canadian Journal of Diabetes*. 2016, 40:173–7. <https://doi.org/10.1016/j.cjcd.2015.08.015>
17. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM: Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. *Metabolism*. 2004, 53:159–64. <https://doi.org/10.1016/j.metabol.2003.07.020>

18. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus. *JAMA*. 2000, 283:1695. <https://doi.org/10.1001/jama.283.13.1695>
19. Bolinder J, Ljunggren Ö, Kullberg J, et al.: Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. *The Journal of Clinical Endocrinology & Metabolism*. 2012, 97:1020–31. <https://doi.org/10.1210/jc.2011-2260>
20. Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA: Short-term effects of metformin in type 2 diabetes. *Diabetes, Obesity and Metabolism*. 2007, 9:483–9. <https://doi.org/10.1111/j.1463-1326.2006.00624.x>
21. Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK: Long-Term Efficacy of Metformin Therapy in Nonobese Individuals With Type 2 Diabetes. *Diabetes Care*. 2006, 29:2361–4. <https://doi.org/10.2337/dc06-0827>
22. Rachmani R, Slavachevski I, Levi Z, Zadok B-S, Kedar Y, Ravid M: Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. *European Journal of Internal Medicine*. 2002, 13:428–33. [https://doi.org/10.1016/s0953-6205\(02\)00131-0](https://doi.org/10.1016/s0953-6205(02)00131-0)
23. Chiasson J-L., Naditch L: The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes. *Diabetes Care*. 2001, 24:989–94. <https://doi.org/10.2337/diacare.24.6.989>
24. Hermann LS, Kalén J, Katzman P, et al.: Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. *Diabetes, Obesity and Metabolism*. 2001, 3:428–34. <https://doi.org/10.1046/j.1463-1326.2001.00160.x>
25. Ji L, Li H, Guo X, Li Y, Hu R, Zhu Z: Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial. *PLoS ONE*. 2013, 8:e57222. <https://doi.org/10.1371/journal.pone.0057222>
26. Kawai T, Funae O, Shimada A, Tabata M, Hirata T, Atsumi Y, Itoh H: Effects of Pretreatment with Low-dose Metformin on Metabolic Parameters and Weight Gain by

- Pioglitazone in Japanese Patients with Type 2 Diabetes. *Internal Medicine*. 2008, 47:1181–8. <https://doi.org/10.2169/internalmedicine.47.0969>
27. Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. *CurrObes Rep*. 2019;8:156-164.
28. Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, Zhu DL. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. *J Diabetes Investig*. 2019;10(2):399-407.
29. Tokhirovna EG. The role of metformin (glififormin) in the treatment of patients with type 2 diabetes mellitus. *Eur J Mod Med Pract*. 2024;4(4):171-177.
30. LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. *Endocr Rev*. 2021;42(1):77-96.
31. Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. *CurrObes Rep*. 2019;8:156-164.
32. Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Diabetes Prevention Program Research Group. Long-term weight loss with metformin or lifestyle intervention in the diabetes prevention program outcomes study. *Ann Intern Med*. 2019;170(10):682-690.
33. Day EA, Ford RJ, Smith BK, Mohammadi-Shemirani P, Morrow MR, Gutgesell RM, Steinberg GR. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. *Nat Metab*. 2019;1(12):1202-1208.

UNDER PEER REVIEW